Medical Science Liaison - New South Wales, Queensland
Apellis Pharmaceuticals
This listing was originally posted on Apellis Pharmaceuticals's careers page. Formulate is an equal opportunity job aggregator and is not involved in the hiring process. Where salary information is estimated, it is derived from BLS industry benchmarks and may differ from actual compensation.
Drug products linked to this role
Upgrade to Pro to access the AI-generated 'Read before applying' briefing and other premium pharma intelligence.
Upgrade to Pro — $25/moOpportunity awaits those up to the challenge of developing transformative therapies across a broad range of debilitating diseases.
Summary:
The Apellis Medical Science Liaison (MSL) is a field based, externally facing scientific role responsible for developing and maintaining peer to peer relationships with key medical experts across New South Wales and Queensland. This position supports our ophthalmology program and plays a critical role in advancing Apellis’ medical strategy through scientific exchange, insights generation, and cross functional collaboration.Roles and Responsibilities:
Scientific Engagement & External Collaboration
Medical Affairs Support
Clinical Development Support
Strategic Planning & Regional Insights
Internal Collaboration
Education, Registration & Certification
Experience
Skills, Knowledge & Abilities
Travel Requirements
Work Arrangement:
Travel Requirements:
This role requires regular travel within NSW and Queensland to engage with healthcare professionals and key stakeholdersEducation:
Benefits and Perks:
Apellis offers a comprehensive benefits package, inclusive flexible time off, summer and winter shutdowns, paid family leave and more!
Company Background:
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases.
For more information, please visit http://apellis.com or follow us on LinkedIn and X.
Other Duties:
Please note this job description is not designed to cover or contain a comprehensive listing of activities, duties or responsibilities that are required of the employee for this job. Duties, responsibilities and activities may change at any time with or without notice.
Explore related positions you might be interested in
We'll notify you when matching roles are posted.
Interviewed at Apellis Pharmaceuticals?
Help others prepare — share your experience anonymously.
PHARMACEUTICAL
Cyclic peptide analog
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access salary benchmarks and market rate data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access all 5 linked drug products and competitive data and other premium pharma intelligence.
Upgrade to Pro — $25/mo